A patent has been granted to TOPADUR Pharma AG in the Greater Zurich Area for its diabetes drug TOP-N53 by the European Patent Office (EPO). According to a press release, the base patent term extends until 2040 and gives protection to the composition of matter for TOP-N53. The EU patent adds to those already granted in the USA, South Africa, Singapore, Philippines, Mexico, Japan, Israel, China and Australia.
“This is a significant and exciting decision by the EPO, and we view this announcement as recognition of TOPADUR’s important contributions to the field of chronic wounds,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG.
The drug is used for the treatment of chronic wounds, which are commonly associated with diabetes. In Switzerland alone, 500,000 people have diabetes, with one in four of these at some point suffering chronic wounds.
In autumn, the European Medicines Agency (EMA) granted TOP-N53 orphan drug designation, so a treatment for medical conditions which are rare. The company reported it was granted Orphan Drug Designation (ODD) for the treatment of digital ulcers in patients with systemic sclerosis (SSc). Digital ulcers are one of the main symptoms associated with SSc. These ulcers often appear on fingers, hands and other parts of the body.
TOPADUR was founded in 2015 and is a member of the Bio-Technopark Schlieren-Zurich.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space